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The Stat5 transcription factors Stat5a and Stat5b have
been implicated in lymphoid development and transfor-
mation. Using the complete Stat5 knockout mice, we have
previously shown that Stat5a/bnull/null cells were resistant to
transformation and leukemia development induced by
Abelson oncogenes, whereas Stat5a/bΔN/ΔN cells readily
transformed. So far, these findings showed distinct sus-
ceptibility to Abelson-induced transformation of Stat5a/
bΔN/ΔN and Stat5a/bnull/null mice and defined Stat5 as key
regulator of initial transformation. In this study, we tested
whether Stat5a/b is also essential for the maintenance of
a transformed state. Therefore we developed a system,
where Stat5a/b could be deleted at will. Abelson-trans-
formed B lymphoid cells were generated from Stat5a/bfl/fl
gene targeted mice that had been crossed with Mx-Cre
transgenic animals. These leukemic Stat5a/bfl/flMxCre cells
were then used to test effects of Stat5a/b ablation in vitro
and in vivo. In vitro, Stat5a/b deletion resulted in a cell
cycle arrest followed by apoptosis. Nine days after dele-
tion, no viable cells could be detected. In line with that, a
down-regulation of Stat5 target genes mediating G1/S
transition within the cell cycle and viability, such as cyclin
D2 and cyclin D3, c-myc and bcl-xL was found. When
leukemic Stat5a/bfl/flMxCre cells were injected into wild
type or immuno-compromised mice leukemia rapidly
developed. Again, deletion of Stat5a/b in vivo within the
leukemic cells significantly counteracted disease progres-
sion as indicated by an increase of leukemia latency from
16 to 49 days. Eventually, all animals succumbed to a
Stat5a/b-positive leukemia indicating that a few residual
cells escaped deletion. Moreover, p53 abruption or over-
expression of the oncogene did not alter the susceptibility
to Stat5 loss of established leukemic cell lines. Taken
together our data define a key role for Stat5a/b not only
for lymphoid development but also for lymphoid trans-
formation. Stat5a/b is necessary for the initial transforma-
tion as well as for leukemia progression. This absolute
necessity for the proliferation and viability of Abelson-
transformed cells puts Stat5a/b into the spotlight of new
therapeutic strategies for the treatment of bcr/abl-induced
leukemias.
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